Emergent BioSolutions Inc. announced that it has entered into an agreement to acquire Adapt Pharma and its flagship product Narcan...
Emergent BioSolutions Inc. announced that the FDA has approved Narcan Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose
The FDA has approved Narcan (naloxone intranasal), from Adapt Pharma, the first FDA-approved nasal spray version of naloxone hydrochloride, to...
Adamis Pharmaceuticals Corporation announced that the FDA has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug...
Indivior Inc., a subsidiary of Indivior PLC announced that it has received a Complete Response Letter from the FDA regarding...
Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT 003 after its approval and launch